Based on the results of the IMspire150 trial, this study found that, over a lifetime horizon, atezolizumab in combination with vemurafenib plus cobimetinib would not be cost-effective at the WTP threshold of $150 000 per QALY for treating patients with newly diagnosed unresectable locally advanced or metastatic BRAF V600 variation melanoma. Here, BRAF is linked to melanoma.